India, Sept. 15 -- Akeso, Inc. (AKESF,9926.HK) announced positive overall survival (OS) results from the Phase III HARMONi-2 study of ivonescimab versus pembrolizumab as first-line treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
NSCLC is the most common type of lung cancer and includes squamous and non-squamous subtypes.
PD-L1 expression is commonly used to help guide treatment with immune checkpoint inhibitors such as pembrolizumab.
Ivonescimab is a next-generation immuno-oncology therapy designed to combine PD-1 pathway inhibition with anti-angiogenesis through its dual-target mechanism.
As of the August 20, 2026 data cutoff, median follow-up was 36 months, with 234 OS even...